ContraFect Corporation (CFRX) financial statements (2021 and earlier)

Company profile

Business Address 28 WELLS AVENUE
YONKERS, NY 10701
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42243047353327
Cash and cash equivalents15248741026
Short-term investments27 224031232
Other undisclosed current assets4712110
Total current assets:47313149363428
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment1111122
Other noncurrent assets1000000
Total noncurrent assets:4411122
TOTAL ASSETS:51353350383630
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5964445
Accounts payable2311220
Accrued liabilities4743323
Employee-related liabilities      2
Debt 1     
Deferred revenue and credits   1
Other undisclosed current liabilities1     (2)
Total current liabilities:61064444
Noncurrent Liabilities
Long-term debt and lease obligation33     
Operating lease, liability33
Liabilities, other than long-term debt29622151410
Deferred revenue and credits111 
Deferred rent credit  1
Other liabilities0000   
Derivative instruments and hedges, liabilities29621141300
Total noncurrent liabilities:32922151410
Total liabilities:381927191854
Stockholders' equity
Stockholders' equity attributable to parent1316631203126
Common stock0000000
Additional paid in capital253228205193166148118
Accumulated other comprehensive loss(0) (0)(0)(0)(0)(0)
Accumulated deficit(240)(212)(199)(162)(146)(118)(92)
Total stockholders' equity:1316631203126
TOTAL LIABILITIES AND EQUITY:51353350383630

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(34)(28)(31)(27)(34)(25)(17)
Operating loss:(34)(28)(31)(27)(34)(25)(17)
Nonoperating income (expense)615(7)115(0)(13)
Other nonoperating expense(2)  (1)(2)  
Interest and debt expense      (12)
Net loss:(28)(13)(38)(16)(29)(25)(43)
Other undisclosed net income attributable to parent      12
Net loss attributable to parent:(28)(13)(38)(16)(29)(25)(30)
Other undisclosed net loss available to common stockholders, basic      (4)
Net loss available to common stockholders, diluted:(28)(13)(38)(16)(29)(25)(35)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(28)(13)(38)(16)(29)(25)(43)
Other undisclosed comprehensive income      12
Comprehensive loss:(28)(13)(38)(16)(29)(25)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)(0)(0) 
Comprehensive loss, net of tax, attributable to parent:(28)(13)(38)(16)(29)(25)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: